We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Interferon-Gamma Release Assays Preferred for Latent TB

By LabMedica International staff writers
Posted on 30 May 2012
Print article
Interferon-gamma release assays (IGRAs) are significantly better than tuberculin skin tests (TST) at predicting progression from latent tuberculosis (TB).

In order to avoid unnecessary treatment, mass therapy of latent TB infection depends above all on the availability and use of adequate screening tests that more accurately predict progression from latent tuberculosis infection (LTBI) to active tuberculosis than the TST does.

Scientists at the Medical School Hanover (Germany) carried out a meta-analysis to qualitatively evaluate the positive predictive value (PPV) and negative predictive value (NPV) for progression of commercial and “in-house” IGRAs and the TST for persons not receiving preventive treatment. The respective IGRA studies were pooled using both a fixed and a random effect model. In all, 1,225 subjects were tested by "in house" IGRAs, 5,194 by commercial IGRAs and 8,479 by TST.

The pooled PPV for progression for all studies using commercial IGRAs was 2.7%, which was statistically significant compared with 1.5% for the TST.

PPV increased to 6.8% for the IGRAs and 2.4% for the TST when only high-risk groups were considered. Pooled values of NPV for progression for both IGRAs and the TST were very high at 99.7% and 99.4%, although significantly higher for IGRAs.

Five studies included in the metaanalysis utilized “in-house” tests; seven used the T-SPOT.TB ELISPOT (Oxford Immunotec Ltd.; Abingdon, UK); four used the QuantiFERON-TB Gold (QFT-G) and 14 used its successor the QuantiFERON-TB Gold In-Tube (QFT-IT), both products of Cellestis Ltd., (Chadstone, Australia). QFT-IT uses whole blood and produces a result within 16 hours and T-SPOT processes peripheral blood mononuclear cells within eight hours measuring the number of interferon-gamma producing cells.

Roland Diel, MD, MPH, the lead authors of the study said, "This is also highly important for tuberculosis control programs, because a test with a high negative predictive value means that therapy for latent tuberculosis can be limited to test-positive contacts without the danger of overlooking some who are truly infected but undetected by the tests."

The authors concluded that progression rates for commercial IGRA blood tests are remarkably higher than those for the TST, but remain low in absolute numbers. The data suggests that IGRAs provide significant benefits over the TST, but that the use of IGRAs, and testing for LTBI in general, should be targeted at high-risk groups. The study was published online on April 5 2012 in the journal Chest.

Related Links:

Medical School Hanover
Oxford Immunotec Ltd.
Cellestis Ltd.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.